Bendamustine effective for some B-cell patients



Results from a study published in the journal Cancer suggest that patients with indolent B-cell non-Hodgkin’s lymphoma (iNHL) are responding well to Bendamustine, a chemo drug generally used to treat chronic lymphocytocic leukemia and some NHLs.


Professor Brad S. Kahl of the University of Wisconsin School of Medicine and Public Health, Maddison, USA


100 patients aged 31-84 years with indolent NHL who had undergone an average of two chemotherapies prior to enrolment and all were rituximab-refractory.


Drug: Bendamustine, a nitrogen mustard anticancer alkylating agent.
Regimen: The patients received intravenous infusions over 60-120 minutes, of bendamustine 120mg/m2 on days one and two every 21 days, for six to eight cycles.


Overall response rate (ORR): 75%
Complete response: 14%
Unconfirmed complete response: 3%
Partial response: 58%


Grade III or IV reversible haematological toxicities included:
-- Neutropenia (61%)
-- Thrombocytopenia (25%)
-- Anaemia (10%).

The most frequent non-haematological adverse events (any grade) included:
-- Nausea (77%)
-- Infection (69%)
-- Fatigue (64%)
-- Diarrhoea (42%)
-- Vomiting (40%)
-- Pyrexia (36%)
-- Constipation (31%)
-- Anorexia (24%).


Two of every three patients who had become rituximab-refractory responded well to the Bendamustine, and that's a good sign since rituximab immunotherapy is cutting edge stuff.

In one sense it's good to see there's another treatment option for B-cell patients whose lymphomas have become daity-refractory, but by and large this looks like little more than the pharmaceutical company's efforts to get their drugs approved for as many maladies as possible, since this iinevitably means more profits.

by Ross Bonander

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...